Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice

Movement Disorders

Volumn 23, Issue 16, 2008, Pages 2267-2302

  Trenkwalder, Clauder ^a,b   Hening, Wayne A ^c   Montagna, Pasquale ^d   Oertel, Wolfgang H ^e   Allen, Richard P ^f,i   Walters, Arthur S ^g,j   Costa, Joao ^h   Stiasny Kolster, Karin ^e   Sampaio, Cristina ^h  

^a Paracelsus Elena Hospital   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g SETON HALL UNIVERSITY   (United States)

^h INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

ⁱ World Association of Sleep Medicine (WASM)

^j International RLS Study Group (IRLSSG)

more..

Author keywords

Evidence based medicine; Guidelines; MDS recommendations; Restless legs syndrome (RLS); Therapy; Treatment

Indexed keywords

AMANTADINE; BENSERAZIDE PLUS LEVODOPA; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CABERGOLINE; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; CLONIDINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; IRON DEXTRAN; LEVODOPA; LISURIDE; MAGNESIUM; METHADONE; OPIATE; OXYCODONE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SUMANIROLE; TOPIRAMATE; TRAMADOL; UNINDEXED DRUG; VALPROIC ACID; ZOLPIDEM;

ACIDOSIS; ANAPHYLAXIS; ASTHENIA; BALANCE DISORDER; BEDTIME DOSAGE; BIOAVAILABILITY; BLOOD CLOTTING TIME; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSCIOUSNESS DISORDER; CONSTIPATION; DAYTIME SOMNOLENCE; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EATING DISORDER; EVENING DOSAGE; EVIDENCE BASED PRACTICE; EXERCISE; FATIGUE; FIBROSIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; IRON OVERLOAD; KIDNEY FAILURE; LEG EDEMA; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MENTAL DISEASE; MONOTHERAPY; NAUSEA; NEUROMUSCULAR BLOCKING; OUTCOME ASSESSMENT; PANCYTOPENIA; PARASOMNIA; PARESTHESIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; RESTLESS LEGS SYNDROME; REVIEW; RHINITIS; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; SLEEP WALKING; SOMNOLENCE; STEVENS JOHNSON SYNDROME; THINKING; THOUGHT DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; UREMIA; URINE RETENTION; VALVULAR HEART DISEASE; VASCULAR FIBROSIS; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; EVIDENCE-BASED MEDICINE; HUMANS; RESTLESS LEGS SYNDROME; TREATMENT OUTCOME;

EID: 61449256613     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22254     Document Type: Review

References (94)

1. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic leg movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988; 12:1845-1848.
2. Trenkwalder C, Stiasny K, Pollmacher T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995;18:681-688.
3. Walker SL, Fine A, Kryger MH. L-Dopa/carbidopa for nocturnal movement disorders in uremia. Sleep 1996;19:214-218.
4. Staedt J, Wassmuth F, Ziemann U, Hajak G, Ruther E, Stoppe G. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crosover trial of pergolide versus L-dopa. J Neural Transm 1997;104:461-468.
5. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999;52:285-290.
6. Benes H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep 1999;22:1073-1081.
7. Eisensehr I, Ehrenberg BL, Rogge Solti S, Noachtar S. Treatment of idiopathic restless legs syndrome (RLS) with slowrelease valproic acid compared with slow-release levodopa/benserazid. J Neurol 2004;251:579-583.
8. Micozkadioglu H, Ozdemir FN, Kut A, Sezer S, Saatci U, Haberal M. Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. Ren Fail 2004;26:393-397.
9. Trenkwalder C, Benes H, Grote L, et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 2007;22:696-703.
10. Happe S, Sauter C, Klosch G, Saletu B, Zeitlhofer J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 2003;48:82-86.
11. Adler CH, Hauser RA, Sethi K, et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial Neurology 2004; 62:1405-1407.
12. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004;27:907-914.
13. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from a 12-week, randomised, placebo-controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-97.
14. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-1423.
15. Bliwise DL, Freeman A, Ingram CD, Rye DB, Chakravorty S, Watts RL. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med 2005;6:141-147.
16. Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006;81:17-27.
17. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52:938-943.
18. Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study - the PRELUDE study. Sleep Med 2006;7:407-417.
19. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006; 67:1034-1039.
20. Trenkwalder C, Stiasny-Kolster K, Kupsch A, Oertel WH, Koester J, Reess J. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord 2006;21:1404-1410.
21. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007;22:213-219.
22. Stiasny-Kolster K, Kohnen R, Schollmayer E, Moller JC, Oertel WH. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004;19:1432-1438.
23. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.
24. Walters AS, Hening WA, Kavey N, Chokroverty S, Gidro-Frank S. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988;24:455-458.
25. Earley CJ, Yaffee JB, Allen RP. Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome. Neurology 1998;51:1599-1602.
26. Wetter TC, Stiasny K, Winkelmann J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52:944-950.
27. Trenkwalder C, Hundemer HP, Lledo A, et al. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study. Neurology 2004;62:1391-1397.
28. Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004;63:2272-2279.
29. Oertel WH, Benes H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology 2006;67:1040-1046.
30. Tergau F, Wischer S, Wolf C, Paulus W. Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine. Mov Disord 2001;16:731-735.
31. Benes H. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome. Sleep Med 2006;7:31-35.
32. Walters AS, Wagner ML, Hening WA, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993;16:327-332.
33. Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord 2005;20:345-348.
34. Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry 1999;60:241-244.
35. Boghen D, Lamothe L, Elie R, Godbout R, Montplaisir J. The treatment of the restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci 1986;13:245-247.
36. Montagna P, de Bianchi LS, Zucconi M, Cirignotta F, Lugaresi E. Clonazepam and vibration in restless leg syndrome. Acta Neurol Scand 1984;69:428-430.
37. Bezerra ML, Martinez JV. Zolpidem in restless legs syndrome. Eur Neurol 2002;48:180-181.
38. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001;38:104-108.
39. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002;59:1573-1579.
40. Lundvall O, Abom PE, Holm R. Carbamazepine in restless legs. A controlled pilot study. Eur J Clin Pharmacol 1983;25:323-324.
41. Telstad W, Sorensen O, Larsen S, Lillevold PE, Stensrud P, Nyberg-Hansen R. Treatment of the restless legs syndrome with carbamazepine: a double blind study. Br Med J (Clin Res Ed) 1984;288:444-446.
42. Perez Bravo A. Topiramate use as treatment in restless legs syndrome. Actas Esp Psiquiatr 2004;32:132-137.
43. Evidente VG, Adler CH, Caviness JN, Hentz JG, Gwinn-Hardy K. Amantadine is beneficial in restless legs syndrome. Mov Disord 2000;15:324-327.
44. Wagner ML, Walters AS, Coleman RG, Hening WA, Grasing K, Chokroverty S. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996;19:52-58.
45. Davis BJ, Rajput A, Rajput ML, Aul EA, Eichhorn GR. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 2000;43:70-75.
46. O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing 1994;23:200-203.
47. Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004;43:663-670.
48. Nordlander NB. Therapy in restless legs. Acta Med Scand 1953;145:453-457.
49. Earley CJ, Heckler D, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 2004;5:231-235.
50. Botez MI, Fontaine F, Botez T, Bachevalier J. Folate-responsive neurological and mental disorders: report of 16 cases. Eur Neurol 1977;15:230-246.
51. Hornyak M, Voderholzer U, Hohagen F, Berger M, Riemann D. Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Sleep 1998;21: 501-505.
52. Aukerman MM, Aukerman D, Bayard M, Tudiver F, Thorp L, Bailey B. Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 2006;19:487-493.
53. Rajaram SS, Rudzinskiy P, Walters AS. Enhanced external counter pulsation (EECP) for restless legs syndrome (RLS): preliminary negative results in a parallel double-blind study. Sleep Med 2006;7:390-391.
54. Garcia-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a world association of sleep medicine - international restless legs syndrome study group consensus conference at the Max Planck Institute. Sleep Med 2007;8:520-530.
55. Ekbom KA. Astenia crurum paraesthetica ("Irritable legs"). Acta Med Scand 1944;148:197-209.
56. Sackett DL, Straus S, Richardson S, Rosenberg W, Haynes RB. Evidence-based medicine: how to practice and teach EBM. 2nd ed. London, UK: Churchill Livingstone; 2000.
57. Lang AE, Lees A. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002;17(Suppl 4):S1-S166.
58. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-213.
59. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-119.
60. Cook DJ, Mulrow CD, Haynes B. Synthesis of best evidence for clinical decisions. In: Mulrow CD, Cook DJ, editors. Systematic reviews, synthesis of best evidence for health care decisions. Philadelphia: American College of Physicians; 1998. p. 5-12.
61. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640-645.
62. Gregoire G, Derderian F, Le Lorier J. Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? J Clin Epidemiol 1995;48:159-163.
63. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-1291.
64. Woolf SH, Battista RN, Anderson GM, Logan AG, Wang E. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol 1990;43:891-905.
65. Kaufman DW, Shapiro S. Epidemiological assessment of drug-induced disease. Lancet 2000;356:1339-1343.
66. Goodman LS, Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill Professional; 2001.
67. Danoff SK, Grasso ME, Terry PB, Flynn JA. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 2001;120:313-316.
68. Voon V, Potenza MN, Thomsen T. Medication-related impulse control and repetitive behaviors in Parkinson's disease. Curr Opin Neurol 2007;20:484-492.
69. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 2006;21:1627-1635.
70. Stiasny K, Moller JC, Oertel WH. Safety of pramipexole in patients with restless legs syndrome. Neurology 2000;55:1589-1590.
71. Garcia-Borreguero D, Winkelman J, Adams A, et al. Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study. Sleep Med 2007;8:119-127.
72. Walters AS, Winkelmann J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001;16:1105-1109.
73. Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002;3:323-327.
74. Tsai MJ, Tsai YH, Huang YB. Compulsive activity and anterograde amnesia after zolpidem use. Clin Toxicol (Phila) 2007;45: 179-181.
75. Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003;26: 819-821.
76. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5:9-14.
77. Garcia-Borreguero D, Kohnen R, Hogl B, et al. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 2007;8:455-463.
78. Benes H, Heinrich CR, Ueberall MA, Kohnen R. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 2004;27:674-682.
79. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000;7(Suppl 1):27-31.
80. Becker PM, Ondo W, Sharon D. Encouraging initial response of restless legs syndrome to pramipexole. Neurology 1998;51:1221-1223.
81. Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med 2002;3(Suppl):S23-S25.
82. Earley CJ, Allen RP. Restless legs syndrome augmentation associated with tramadol. Sleep Med 2006;7:592-593.
83. Polo O, Yla-Sahra R, Hirvonen K, Karvinen J, Vahteristo M, Ellmen J. Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. Clin Neuropharmacol 2007; 30:335-344.
84. Garcia-Borreguero D, Grunstein R, Sridhar G, et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 2007;8:742-752.
85. Manconi M, Ferri R, Zucconi M, et al. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med 2007;8:491-497.
86. Oertel WH, Benes H, Garcia-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008;9:228-239.
87. Conti CF, de Oliveira MM, Andriolo RB, et al. Levodopa for idiopathic restless legs syndrome: evidence-based review. Mov Disord 2007;22:1943-1951.
88. Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604.
89. Trenkwalder C, Hogl B, Benes H, Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med 2007;9:572-574.
90. Earley CJ, Horska A, Mohamed MA, Barker PB, Beard JL, Allen RP. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med (in press).
91. Sommer M, Bachmann CG, Liebetanz KM, Schindehutte J, Tings T, Paulus W. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 2007;115:347-350.
92. Hornyak M, Grossmann C, Kohnen R, et al. Cognitive behavioral group therapy to improve patients scoping strategies with restless legs syndrome: a proof-of-concept trial. J Neurol Neurosurg Psychiatry 2008;79:823-825.
93. Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007;39:1000-1006.
94. Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007;357:639-647.